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Full mutation phenotypeAbstract Background: Fragile X syndrome (FXS) is the most common form of inherited mental
retardation. Frequency of fragile X syndrome among male siblings and relatives of mentally
retarded patients is relatively high. Cytogenetic diagnosis of FXS is unreliable since it is ineffective
for the diagnosis of premutated males or females. Proper molecular diagnosis is a pre-requisite for
providing proper counseling advice.
Subjects and methods: Sixty-four males with idiopathic mental retardation, ranging in age from
4.2 to 19 years (10.92 ± 4.00) were clinically pre-selected, based on scoring protocol comprising
eight features of the syndrome, before molecular testing. A rapid polymerase chain reaction-
based screening was applied for detection of expanded FMR1 alleles. Samples that did not yield
the normal band lengths were subjected to a second PCR screen. The secondary screen utilizes a
chimeric primer demonstrating the presence or absence of an expanded allele.
Results: Amplification of FMRI gene by PCR of tested patients revealed that 8 cases (12.5%)
have full mutation and 6 cases (9.4%) have premutation. A wide range of Fra X-scoring ranging
from 1 to 7 features was detected in examined cases. Significant clinical features included large
prominent ears, hyperextensibility of joints and macroorchidism in post pubertal males.
Conclusions: A simplified checklist of fragile X should be used for patients with idiopathic MR
and those patients above score 3 should be tested for FXS. The diagnostic assay may be used as a
screening method for fragile X syndrome being rapid and cost effective compared to other
techniques. In addition, screening of all relatives of proven patients should be performed to detect
clinically unidentified cases for provision of proper counseling and optimal management of detected
cases.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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X-chromosome fragility is a genetic defect that underlies the
pathogenesis of a wide spectrum of clinical syndromes headed
by fragile X mental retardation. The fragile X mental retarda-
tion (FMR) gene regulates the synthesis of a protein, fragile X
mental retardation protein (FMRP), an RNA-binding protein
that plays an important role in regulating proliferation and
differentiation of adult neural stem-progenitor cells. The muta-
tion of the FMR gene results in drastic consequences on many
neural functions including memory, cognition and behavior,
hence the wide clinical spectrum of disorders caused by this
genetic defect [1]. The mutational basis of the genetic defect
resides in pathological expansion of the normally existing
45–55 repeats of CGG bases in the wild-type FMR gene to
many times this number, up to many hundreds, in the genes
of patients. The resulting pathophysiological alterations pave
the way to the development of the many disorders, notably
fragile X syndrome, autism and other less well-characterized
neuro-psychiatric phenotypes. Lesser increases, short of 200
repeats, occur in carriers or pre-mutation states [2]. Fragile X
syndrome (FXS) is the most common form of inherited mental
retardation. Cytogenetic diagnosis of the syndrome depends on
visually revealing the fragility of the terminal portion of the
long arm of the X chromosome of affected patients in cell
culture. However, this cytogenetic diagnostic approach is unre-
liable, particularly within the context of provision of genetic
counseling advice, since it is ineffective for the diagnosis of
pre-mutated males or females. On the contrary, molecular diag-
nosis of the mutational defect of the FMR gene provides an
accurate, reliable and definitive diagnosis of the genetic defect
[3]. A lot of studies have pointed to the finding of this peculiar
genetic defect in many genetically-determined diseases, includ-
ing autism and psychiatric-behavioral disorders. It has been
estimated that fragile X gene mutation, probably, underlies
the etiology of autism of 2–6% of autistic children. Even more
remarkable is the fact that between 15% and 30% of boys with
fragile X syndrome meet the diagnostic criteria of autism [4].
2. Aim of the work
The present study aims at molecular detection of the fragile X
mental retardation gene mutations among a sample of Egyptian
male patients with isolated idiopathic mental retardation. Inclu-
sion of isolated idiopathic cases of mental retardation in the
study is intended for two purposes. First, revealing the inci-
dence of the defect in this category of patients who are subjected
to many diagnostic tests, including conventional cytogenetic
studies, without being tested for this particular genetic defect,
and second, obviating the possibility of skipping their proper
molecular diagnosis which is a pre-requisite for providing
proper counseling advice to their family members. In addition,
the results of the studymight contribute to better understanding
of genotype–phenotype correlations in male cases with isolated
idiopathic mental retardation.
3. Subjects and methods
The present study was carried out on 64 male patients with iso-
lated idiopathic mental retardation selected from outpatient
clinic inNeuromotor systemNational Institute and theGeneticsClinic, Pediatrics Hospital of Ain-Shams University. Their ages
ranged from 4.2 to 19 years, with a mean age of (10.92 ± 4.00).
Thirty-seven patients (57.8%) were more than 10 years of age.
The remaining 27 (42.2%) were less than 10 years of age. Seven
cases (50%) were diagnosed at ages 5–10 years.
Selection criteria for isolated and idiopathic mental retarda-
tion included: idiopathic mental retardation, absence of
pathognomonic features of known recognizable syndromes,
absence of signs and/or findings suggestive of chromosomal
cause of their disease, absence of symptoms suggestive of
underlying metabolic etiology with normal metabolic screen,
absence of radio-imaging findings of morphological brain
defects, absence of prenatal/postnatal history suggestive of a
perinatal insult, including intrauterine infections and absence
of postnatal history suggestive of a relevant head trauma or
brain infection.
All cases included in the study were subjected to: (1) Com-
plete history taking with special emphasis on aspects related to
the idiopathic nature of their mental retardation, including:
full details about prenatal, perinatal, immediate post natal his-
tory and neonatal intensive care unit admission (NICU), past
history including history of head trauma and CNS infections
and complete family history, pedigree construction and
detailed genealogical study of the family pedigree. (2) Thor-
ough clinical examination was done for all cases including:
weight, height, head circumference and examination of the dif-
ferent body systems with special emphasis on neurological
examination and eight fragile X (FXS) features. The eight
items score used in this study included family history of MR,
long face, large prominent ears, hyperextensibility of the finger
joints, macroorchidism (in post pubertal males), hyperactivity,
autistic features and unusual speech pattern [6–8]. In addition,
IQ testing was done according to Stanford–Binet Intelligence
Scale test [9]. (3) Mutation analysis of the FMR gene triplet
repeat expansion defects was performed according to the tech-
nique described by Tassone et al. [5] on blood samples
obtained from patients, following informed consent from par-
ents or guardians.
The work has been carried out in accordance with the code
of Ethics of the World Medical Association (Declaration of
Helsinki) for experiments involving humans, and acceptance
of The Ethical Committee of Ain-Shams University.
(A) DNA extraction: Whole peripheral blood samples will
be collected on EDTA (1 ml on the average) and stored in
20 C till processing: Genomic DNA was extracted from
peripheral blood lymphocytes by spin column method of
GeneJETTM purification kit (#K072, PureExtreme Fermentas
Life Sciences, Thermo Scientific, Vilnius, Lithuania).
(B) Selection and synthesis of oligonucleotides (according
to the published nucleotide sequences, and Gene bank data
base): The study comprised the application of the screening
technique published before [5] for detection of both permuta-
tion and mutation statuses of examined cases. Genomic
DNA was amplified by PCR with primers c and f using the
osmolite betaine according to Fu et al. [10] and Saluto et al.
[11].
Primer c (50-GCTCAGCTCCGTTTCGGTTTCACTTCC-
GGT-30).
Primer f (50-AGCCCCGCACTTCCACCACCAGCTCCT-
CCA-30).
Standard primer PCR reactions were performed using the
Expand Long Template PCR System (Sigma diagnostics).
Table 1 Frequency of consanguinity in the population of the
study.
Consanguinity Unexpanded
allele
Full and pre
mutation
Total
N % N % N %
Negative 32 64 11 78.6 43 67.2
Positive 18 36 3 21.4 21 32.8
Total 50 100.0 14 100.0 64 100.0
Chi-square
v2 1.053
P-value 0.305*
* Significant P-value < 0.05.
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diagnostics) 500-mol/L dNTPs, 0.33-M of each primer, and
200 ng of genomic DNA. The PCR buffer also included
2.2 M betaine (B0300; Sigma–Aldrich). The use of modified
amino acid betaine is to permit PCR amplification of very
GC-rich sequences and due to the stabilizing action on the
polymerases, in addition, it allows consistent detection of
expanded alleles throughout the premutation range. The
PCR products could be directly visualized on agarose
[12,13]. It overcomes low levels of contaminants that can
co-purify with DNA [14].
In vitro amplification was performed on gradient thermal
cycler (HYBAIDExpress;HYBAIDLimited,Ashford,Middle-
sex, United Kingdom). The PCR cycling profile was as follows:
denaturation at 98 C for 10 min, 10 cycles at 97 C for 35 s,
64 C for 35 s, and 68 C for 4 min; 25 cycles at 97 C for 35 s,
64 C for 35 s, 68 C for 4 min plus a 20-s increment for each
cycle; and a final extension at 68 C for 10 min. The expected
PCR fragment region (excluding the CGG repeat region) was
221 bp. The genotypes of the PCR products were determined
by electrophoresis on 2% agarose gels stained with ethidium
bromide in 1x Tris–EDTA (ethylenediamine tetraacetic acid)-
Borate buffer (TBE) against 50 bp ladder molecular weight
GeneRulerTM 50 bp DNA ladder (FermentasTM, #SM0373,
Thermo Scientific/Fermentas, Vilnius, Lithuania). In case of
testing males (like in our study) samples that did not yield the
normal band, were subjected to a second PCR screen with the
c primer and the CCG-chimeric primer (50-AGCGTC-
TACTGTCTCGGCACTTGC(CCG)4-30; targeting the CGG
strand of the repeat expansion tract) in place of the f primer.
The secondary screen demonstrates the presence of an expanded
allele. This is also true for mosaic males, both for repeat size
(presence of both premutation and full-mutation alleles)
and/or for methylation (presence of partially methylated, full-
mutation alleles).
The PCR products were all documented by Gel Documen-
tation System and Software for DNA analysis (InGenius
SyngeneTM, UK).
Statistical analysis of data was done using statistical pro-
gram for social science (SPSS) version 18.0. Quantitative data
were expressed as mean ± standard deviation (SD). Qualita-
tive data were expressed as frequency and percentage.
Independent-samples t-test of significance was used when com-
paring between two means. Mann Whitney U test: for two-
group comparison in non-parametric data. Chi-square (v2) test
of significance was used in order to compare proportion
between two qualitative parameters. ANOVA tests were done
for comparison among different items in the same group in
quantitative data. Probability (P-value) P-value < 0.05 was
considered significant. P-value < 0.001 was considered highly
significant. P-value > 0.05 was considered insignificant.
4. Results
A total of 64 children with idiopathic cause of mental retarda-
tion were analyzed in the present study. They presented with a
history of developmental delay, cognitive dysfunction, speech
and behavioral problems. The age of the patients ranged from
4.2 to 19 years with a mean of 10.92 ± 4.00. There was no sig-
nificant difference among patients as regards consanguinity
(Table 1). Patients’ IQ ranged from 20 to 85 with a mean of63.08 ± 10.61, Table 2. Mild MR was the commonest type
of MR 62.5%. There was no significant difference in IQ level
between patients with full or permutation (f= 0.272, P-value
0.763). Out of the 64 mentally retarded patients, 8 (12.5%)
children had full mutations, 6 children (9.4%) had pre muta-
tion (Tables 2 and 3).
There was a significant difference in different groups as
regards clinical score demonstrating that 37.5% of patients
with full mutation had 7 criteria of the score, followed by
25% each for 4 criteria and 6 criteria. In patients with permu-
tation 33.3% had 4 criteria of the score, while in patients with
unexpanded allele 26% had 4 criteria and 18% had 6 criteria
of the score. There was a significant difference in range of clin-
ical scoring between patients with full mutation and those
without expanded allele (Tables 4 and 5).
Comparison of the studied eight fragile X-related features
in Fra X males (full and permutation) and non Fra-X MR
males showed a significant association between large
prominent ears, hyper extensibility of joints and macroorchid-
ism (in post pubertal males), and FXS diagnosis (P-value =
0.042, 0.040, 0.003 respectively). Comparison of the studied
eight fragile X-related features in Fra X males with full
mutation and Fra X males with permutation showed a
significant association between large ears, macroorchidism
(in post pubertal cases) and long face and FXS full mutation
(P-value = 0.024, 0.016, 0.031 respectively) with the exception
of one boy having permutation with severe autistic features his
Cars test was 40 (Table 6). Comparison between the presence
of features in those above and below 10 years of age for Fra
X positive cases (full and permutation) showed significant
difference for macroorchidism and hyperextensibility of
joints (P-value = 0.010, 0.036 respectively) and insignificant
difference for other features. Comparison of the percentage
of seizures and/or abnormal EEG finding in Fra X males (full
and permutation) and non-Fra-X MR males showed a total of
35.7% of our FXS children had a history of seizures and
abnormal EEG with no significant difference (data not shown
in tables) (see Fig. 1).
5. Discussion
The target population in our study was patients with idio-
pathic mental retardation and developmental disabilities, as
these characteristics are highly suggestive of fragile X
Table 2 FRAXA genotyping among patients.
Results No. of patients %
Genotype
1-Full mutation 8 12.5
2-Premutation 6 9.4
3-Unexpanded allele 50 78.1
Total 64 100.0
Table 3 IQ and MR levels among patients.
Results No of patients %
IQ and MR
1-Subnormal (70–85) 13 20.4
2-Mild (70–50) 40 62.5
3-Moderate (50–35) 10 15.6
4-Profound (below 20) 1 1.6
Total 64 100.0
Table 4 Score for the eight Fra X-related features among
patients in relation to degree of mutation.
Scoring Full mutation Premutation Unexpanded allele
N % N % N %
1 0 0 1 16.7 3 6.0
2 0 0.0 1 16.7 8 16.0
3 1 12.5 0 0.0 10 20.0
4 2 25.0 2 33.3 13 26.0
5 0 0.0 1 16.7 6 12.0
6 2 25.0 1 16.7 9 18.0
7 3 37.5 0 0.0 1 2.0
Total 8 100.0 6 100.0 50 100.0
Chi-square
v2 19.936
P-value 0.048*
* Significant P-value < 0.05.
168 H.A. Hosny Omar et al.syndrome (FXS). It is of prime importance to screen patients
demonstrating symptoms of FXS and to increase the detection
rate for this disease. One of the main impediments to the
implementation of screening for expanded alleles of theTable 5 Range of clinical scoring in the population of the study.
Scoring
Range
Full Mutation 3–7
Premutation 1–6
Unexpanded allele 1–7
Tukey’s test
Full mutation and premutation Full mutation and unexpanded
0.091 0.021*
* Significant P-value < 0.05.FMR1 gene has been the absence of a rapid, inexpensive
screening tool that would be capable of detecting all expanded
alleles in both males and females [5].
In the current work, we have applied the new PCR-based
approach for FMR1 genotyping that combines modification
of the betaine protocol previously described [5,11] with use
of CGG-targeted (chimeric) primer. It generates an extensive
distribution of PCR products only in the presence of premuta-
tion or full-mutation alleles. Providing a single band indicative
of a full mutation, has been the goal of previous, but unsuc-
cessful methods. The current method results in a broad smear
as a result of amplifications of multiple different lengths. The
smear is indicative of the presence of a full mutation. A sample
from an individual without an expanded allele will not create a
large smear. This method is extremely rapid and permits the
test to be integrated, with the routine screening [12]. This
means that as a screening tool, all males can be typed with
no requirement for a secondary screening tool [5]. Many differ-
ent restriction enzymes can be used in combination to deter-
mine both expansion and methylation statuses for an
individual [15]. The main disadvantage of Southern blot - the
most accepted method for testing the expanded CGG repeat
- is that it requires a large amount of DNA and is laborious,
both of which are features that prevent the rapid and inexpen-
sive screening [16]. Compared with Southern blots, the PCR
test is inexpensive, automated, and fast. It can be performed
on very small amounts of DNA. For many other PCR proto-
cols, the DNA fragment with the expanded repeat does not
amplify. This is especially problematic for females and persons
with repeat-size mosaicism who could appear to have a single,
normal repeat size [17,18]. In the protein-based assay, the per-
centage of FMRP detected in lymphocytes from blood smears
is used to determine affection status [19–21]. Typically, fewer
than 40% of the lymphocytes from males with the fragile X
syndrome have detectable amounts of FMRP [20]. This
protein-based test has been adapted for hair root [22,23] and
prenatal samples [24,25]. This technique cannot accurately
identify affected females [26]. The currently applied method
permits determining whether an individual either has a premu-
tation in the gene known to have 55 to up to 200 repeats and is
therefore a carrier, or has a full mutation in the gene known to
be above 200 repeats which are generally hypermethylated,
and the gene is silenced [27]. A primary screening tool does
not need to define the exact size of a full mutation allele, but
only to signal its presence. The ability to early diagnose per-
sons with FXS can reduce the burden of this disorder on the
individual, on the individual’s family, and on society in some
embodiments [12].ANOVA
Mean ± SD f P-value
5.50 ± 1.60 3.937 0.025*
3.67 ± 1.86
3.84 ± 1.56
allele Premutation and unexpanded allele
0.965
Table 6 Comparison between the studied eight fragile X-related features in Fra X males with full mutation, permutation and non-
fragile X MR Males.
Fragile X-related features Unexpanded allele (n= 50) Full and pre mutation (n= 14) Chi-square
N % N % v2 P-value Sig.
Large ears 24 48.0 11 78.6 4.125 0.042* Sig.
Hyper extensibility of joints 14 28.0 8 57.1 4.118 0.040* Sig.
Family history of MR 28 56.0 8.0 57.1 0.006 0.939 N Sig.
Macroorchidism (in postpubertal cases) 3 6.0 5 28.6 5.720 0.003* Sig.
Hyperactivity 31 62.0 9 64.3 0.024 0.876 N Sig.
Autistic features 18 36.0 8.0 57.1 2.027 0.155 N Sig.
Abnormal speech pattern 42 84.0 10.0 71.4 1.135 0.287 N Sig.
Long face 24 48.0 7.0 50.0 0.018 0.895 N Sig.
Fragile X-related features Full mutation (n= 8) Premutation (n= 6) Chi-square
N % N % v2 P-value Sig.
Large ears 8 100.0 3.0 50.0 5.091 0.024* Sig.
Hyper extensibility of joints 4 50.0 4 66.7 0.389 0.389 N Sig.
Family history of MR 4 50.0 4.0 66.7 0.389 0.533 N Sig.
Macroorchidism (in postpubertal cases) 5 50.0 0.0 0.0 4.200 0.016* Sig.
Hyperactivity 6 75.0 3.0 50.0 0.933 0.334 N Sig.
Autistic features 5 62.5 3.0 50.0 0.219 0.640 N Sig.
Abnormal speech pattern 7 87.5 3.0 50.0 2.363 0.124 N Sig.
Long face 6 75.0 1.0 16.7 4.667 0.031* Sig.
* Significant P-value < 0.05.
Figure 1 Showing a 2% agarose gel of PCR products. Lane 1:
amplified normal PCR product of normal alleles (220 bp) (absent
in affected males). Lane 2: a full-mutation, an extensive smear is
produced reflecting expanded CGG repeat. Lanes 3 and 4: only
small PCR products are produced (expanded alleles). Lane 5:
100 bp DNA ladder molecular weight GeneRulerTM.
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tion in general population is estimated at 1 in 813 men [59] and
1 in 259 women [60–62]. Our incidence is much higher proba-
bly due to screening of isolated idiopathic MR patients and the
selection criteria used. The prevalence of FXS full mutation in
examined cases was 12.5% and that of permutation was 9.4%.
A cytogenetic analysis, conducted by El Sobky et al. [28] on
twenty mentally retarded boys, estimated the frequency to be
approximately 20%. A molecular survey reported a frequency
of 6.4% of fragile X syndrome among 400 children with men-
tal sub-normality from school age Egyptian males [29].
Another study with reverse transcriptase (RT)-PCR method
revealed a frequency of 17% fragile X syndrome full mutation
among males with MR [8]. Our results were comparable with a
recent study conducted on 53 males with mental sub-
normality, speech disorder and score of 16 or higher in Hager-man’s checklist [30].The prevalence of fragile X syndrome full
mutation was 15% and that of permutation was 5.6% [31].
The frequency of FXS presented in this study is higher than
that reported for Caucasian populations where it accounted
for 2.6–8.7% among patients with mental retardation
[32–34]. Comparing with Far Eastern populations, an inter
population diversity was noted in the prevalence of FXS.
Our frequency rates were found to be higher than those
observed in Chinese mentally retarded patients (2.8–3.2%)
[35]. Similar difference was noted between our data and a
report of 0.8–2.4% frequency in patients with mental retarda-
tion among Japanese population [36,37]. A relatively lower
frequency of fragile X syndrome (1.9%) among the mentally
retarded individuals was reported from Southern Taiwan
[38]. Comparing with Indian population during the last two
decades, our frequency rates were found to be higher than that
detected by a cytogenetic analysis (2%) [39] and 5.3%
frequency of fragile X syndrome among children with unex-
plained mental retardation [40]. Among Kuwaiti mentally
retarded patients the frequency of fragile X syndrome is
reported to be 11% [41]. Iqbal et al. [42] reported a frequency
of 14.8% in Saudi cases of mental retardation. Among Turkish
patients with mental retardation the frequency was 12.8% [43].
Among Iranians, a frequency of 6.3% was reported [44]. The
relatively high prevalence of fragile X syndrome within the
Arab, other Asian populations and our results may be due
to pre selection criteria of study subjects on the basis of clinical
phenotype of FXS. Our selection criterion was mental retarda-
tion or learning disabilities of unknown etiology. Therefor, the
variability of percentage in different studies may be due to
difference in sample size, age of the patients, different selection
criteria and different detection techniques.
Among our patients, 56.25% of the children had positive
family history for mental retardation and 32.8% of mentally
retarded children had consanguineous parents, 78.6% of
170 H.A. Hosny Omar et al.fragile X patients had non-consanguineous parents despite
that consanguineous marriage is high in Egypt as reported
by Shawky et al. [45].
In the present study, 57.1% of fragile X children had posi-
tive family history for mental retardation either from paternal
or maternal side, without parental consanguinity. Different
frequencies have been reported elsewhere; 13.9% by Carpenter
et al. [46], 3.6% by Froster-Iskenius et al. [47] and 14.8% by
Iqbal et al. [42]. Bastaki et al. [41] reported that 85% of
patients had affected siblings and 70% of the patients had
affected relatives. On the basis of present and past studies, it
is apparent that frequency of FXS among the siblings and
relatives of mentally retarded patients is relatively high. Pouya
et al. [44] observed a familial effect on the prevalence of FXS in
children with consanguineous parents, however, offspring of
non-consanguineous parents also had FXS. Meguid et al.
[29] rated consanguinity to be the major cause for higher rate
of FXS among Egyptian subnormal patients.
Assessment of fragile X clinical features revealed that it is
not necessary to detect all features in all of the patients at
one time. The clinical picture of FXS is fairly characteristic
in post-pubertal males. The classical features comprise a triad
consisting of long face with large and prominent ears, mental
retardation and macroorchidism [48–51]. Clinical diagnosis
of FXS in younger children is hindered by the inconsistent
expression of the characteristic craniofacial features [51–54].
The presence of different features is reported to vary with
age [52,54]. In order to determine whether a set of the most
observed fragile X characteristics from the eight-item fragile
X checklist would improve selection of individuals at risk,
we retrospectively scored all children. Our results showed that
the mean score for the fragile X group with full mutation pos-
itive findings was 5.5 and 3.67 for fragile X full mutation and
pre-mutation respectively. These findings are in agreement
with those of Giangreco et al. [6] indicating that genetic anal-
ysis of the FXS can be restricted to selected males.
In the present study, the size of the testes was checked. Five
fragile X positive cases (35.7%) had macroorchidism com-
pared to 3 (6%) fragile X negative cases. The frequency of
macroorchidism in FXS varies from 11% to 80% [41,42,55].
Among studied cases, 57.1% of fragile X children had
autistic-like behavior. A relationship between autism and frag-
ile X syndrome has been suggested in various studies [56].
Among autistic patients, 4.3% showed CGG repeat expansion
[57]. A comparable incidence (45%) has been reported [41], but
most of these patients were in the post-pubertal stage. Other
studies reported a lower incidence of autism (10.7%) among
fragile X syndrome patients [42]. In addition to mental
retardation, which can range from mild to severe, behavioral
problems such as hyperactivity, lack of attention, autism
spectrum disorders, repetitive and disorderly language have
been found to be common in affected males [34,58].
In the present study, the frequency of fragile X-related fea-
tures among our FXS children (including hyperactivity disor-
der, perseverant speech/difficulty in speaking words, long
face, hyperextensibility of joints and large ears) is consistent
with that of Guruju et al. [56] who observed a 15-item checklist
of characteristic clinical features for the identification of FXS.
Comparable results were detected by Bastaki et al. [41] who
found that 85% of fragile X cases had hyperactivity, 85%
had defective speech and 90% had large ears. Although sei-
zures were noted as common clinical symptom in our mentallyretarded subjects, a total of 35.7% of our FXS children had a
history of seizures and/or abnormal EEG finding. These results
were in accordance with those of other authors [41].
The clinical presentation of children with permutation was
variable. Their IQ ranged between 45 and 80 with variable
degree of hyperactivity and moderate to severe anxiety. Similar
observation was noted by Yim et al. [63]. It has been docu-
mented that children with the premutation alleles have cogni-
tive deficits, behavioral problems and/or autism spectrum
disorder [64–66]. Learning problems, developmental delay
and/or autistic features have been identified in boys with pre-
mutation; these symptoms were observed in our group of boys
with premutations. Attention problems in most premutation
individuals seem to be milder than those seen in full mutation
carriers. This clinical picture may be related to mild fragile X
mental retardation protein (FMRP) deficits commonly
reported in affected children with the premutation [67,68].
Similar observation has also been reported in some children
with diagnosis of autistic spectrum disorder and premutation
[64]. Premutation carriers can be detected only by direct molec-
ular analysis of the fragile X mental retardation gene repeat
number because they may lack abnormal clinical features as
seen in milder forms of FXS such as autistic features and
developmental delay [69].
In view of the relatively small number of cases enrolled in
this study, more large-scale studies should be carried out to
assess the current practice of pediatric screening when there
is developmental delay. Larger samples of patients are needed
to verify the actual incidence of the disease and the usefulness
of the method used in the present study. This assay may be
used as a screening method for FXS being rapid and cost effec-
tive compared to other techniques A simplified checklist of
fragile X should be used for patients with MR and those
patients above score 3 should be tested for fragile X. In addi-
tion, screening of all relatives of proven patients should be
done to detect other clinically unidentified cases is mandatory
for provision of proper counseling advice and management
protocols for detected cases.Conflict of interest
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